ArticleCureus2025
Prevalence and Evolution of Thyroid Dysfunction in COVID-19: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Coronavirus-19 (COVID-19) is known to mainly affect the respiratory system, but it has also been found to impact multiple endocrine systems. Various studies have shown a relationship between thyroid dysfunction and COVID-19 infection. However, there is controversy around thyroid-inflammatory autoimmune conditions contributing to a worse prognosis of COVID-19 infection. The main objective of our single-center retrospective study is to evaluate the prevalence and evolution of thyroid dysfunction in patients with COVID-19 infection. Methods A total of 615 adults with confirmed COVID-19 infection, between March 2020 and December 2023, who had thyroid function tests (TFTs), were included in the study. Patients with pre-existing thyroid disease or on medications affecting thyroid function were excluded. Thyroid dysfunction was defined as any abnormality in TFTs. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 26 (Released 2018; IBM Corp., Armonk, NY, USA). Differences in continuous variables were assessed using independent sample t-tests, and Pearson's Chi-square tests were used to compare categorical variables. Results The study showed that 84 patients (13.6%) had thyroid dysfunction. The most common abnormalities were non-thyroidal illness syndrome (NTIS, n = 39; 46.4%) and subclinical hypothyroidism (n = 37; 44%), followed by overt hyperthyroidism (n = 6; 7.1%) and overt hypothyroidism (n = 2; 2.3%). The evolution of thyroid dysfunction was followed for about one year by chart review and showed no progression to overt thyroid dysfunction. Conclusion We noted that thyroid dysfunction is not uncommon in patients with COVID-19, with subclinical hypothyroidism and NTIS being the most prevalent findings. These abnormalities are often transient and resolve without progression in most cases. The pathogenesis appears to involve both direct viral effects and systemic inflammatory responses. Given the potential overlap between thyroid dysfunction and long COVID symptoms, selective monitoring of thyroid function is warranted in symptomatic individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.